What ANI Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 11 | 49 |
| Total trades | 12 | 106 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 6,662 | 223,442 |
| Disposed | 30,412 | 363,667 |
| Net activity | −23,750 | −140,225 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Lalwani Nikhil | PRESIDENT & CEO | Oct 15 | Disclosed 10b5-1 sale · S | −5,400 | $71.89 | −$388K | 333,689 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Oct 13 | Open-market sale · S | −500 | $73.59 | −$36.8K | 73,424 |
| Carey Stephen P. | SVP & CFO | Sep 29 | Disclosed 10b5-1 sale · S | −2,850 | $73.00 | −$208K | 168,993 |
| Lalwani Nikhil | PRESIDENT & CEO | Sep 15 | Disclosed 10b5-1 sale · S | −5,400 | $71.00 | −$383K | 339,089 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sep 14 | Open-market sale · S | −500 | $70.79 | −$35.4K | 73,924 |
| Thoma Jeanne | Director | Sep 11 | Disclosed 10b5-1 sale · S | −1,000 | $71.53 | −$71.5K | 26,762 |
| Carey Stephen P. | SVP & CFO | Aug 31 | Disclosed 10b5-1 sale · S | −2,850 | $72.80 | −$207K | 171,843 |
| Lalwani Nikhil | PRESIDENT & CEO | Aug 25 | Disclosed 10b5-1 sale · S | −5,400 | $74.30 | −$401K | 344,489 |
| Gosebruch Henry O | Director | Aug 19 | Grant / award · A | +6,662 | — | — | 6,662 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Aug 13 | Open-market sale · S | −500 | $75.48 | −$37.7K | 74,424 |
| Gutwerg Ori | SVP, GENERICS | Aug 10 | Open-market sale · S | −3,162 | $77.00 | −$243K | 75,534 |
| Carey Stephen P. | SVP & CFO | Jul 29 | Disclosed 10b5-1 sale · S | −2,850 | $81.36 | −$232K | 174,693 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Jul 18 | Withheld — tax / exercise cost · F | −2,466 | $79.20 | −$195K | 74,924 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Jul 13 | Open-market sale · S | −500 | $81.84 | −$40.9K | 77,390 |
| Carey Stephen P. | SVP & CFO | Jul 02 | Open-market sale · S | −3,313 | $86.00 | −$285K | 177,543 |
| Carey Stephen P. | SVP & CFO | Jul 02 | Exercise / conversion · M | +3,313 | $49.51 | +$164K | 180,856 |
| Carey Stephen P. | SVP & CFO | Jun 29 | Disclosed 10b5-1 sale · S | −2,850 | $84.12 | −$240K | 177,543 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Jun 12 | Open-market sale · S | −500 | $82.03 | −$41K | 77,890 |
| Haughey Thomas | Director | Jun 08 | Disclosed 10b5-1 sale · S | −2,000 | $80.88 | −$162K | 38,878 |
| Carey Stephen P. | SVP & CFO | Jun 05 | Open-market sale · S | −3,312 | $80.00 | −$265K | 180,393 |
Loading...
